Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates

References

• Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, et al. (2019). Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. J Cell Physiol 234:5628–42.
   PubMed Web of Science ®Google Scholar
• Bargh JD, Isidro-Llobet A, Parker JS, Spring DR. (2019). Cleavable linkers in antibody-drug conjugates. Chem Soc Rev 48:4361–74.
   PubMed Web of Science ®Google Scholar
• Bargh JD, Walsh SJ, Isidro-Llobet A, et al. (2020). Sulfatase-cleavable linkers for antibody-drug conjugates. Chem Sci 11:2375–80.
   PubMed Web of Science ®Google Scholar
• Burke PJ, Senter PD, Meyer DW, et al. (2009). Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues. Bioconjug Chem 20:1242–50.
   PubMed Web of Science ®Google Scholar
• Cardillo TM, Govindan SV, Zalath MB, et al. (2018). IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma. Mol Cancer Ther 17:150–60.
   PubMed Web of Science ®Google Scholar
• Chau CH, Steeg PS, Figg WD. (2019). Antibody-drug conjugates for cancer. Lancet 394:793–804.
   PubMed Web of Science ®Google Scholar
• Coats S, Williams M, Kebble B, et al. (2019). Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index. Clin Cancer Res 25:5441–8.
   PubMed Web of Science ®Google Scholar
• Dal Corso A, Borlandelli V, Corno C, et al. (2020). Fast Cyclization of a Proline-Derived Self-Immolative Spacer Improves the Efficacy of Carbamate Prodrugs. Angew Chem Int Ed Engl 59:4176–81.
   PubMed Web of Science ®Google Scholar
• Dong W, Shi J, Yuan T, et al. (2019). Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan. Eur J Med Chem 167:583–93.
   PubMed Web of Science ®Google Scholar
• Doronina SO, Toki BE, Torgov MY, et al. (2003). Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778–84.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Cardillo TM, Govindan SV, et al. (2015). Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget 6:22496–512.
   PubMed Web of Science ®Google Scholar
• Govindan SV, Cardillo TM, Sharkey RM, et al. (2013). Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol Cancer Ther 12:968–78.
   PubMed Web of Science ®Google Scholar
• Hafeez U, Parakh S, Gan HK, Scott AM. (2020). Antibody-Drug Conjugates for Cancer Therapy. Molecules 25:4764.
   PubMed Web of Science ®Google Scholar
• Kalim M, Chen J, Wang S, et al. (2017). Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates. Drug Des Devel Ther 11:2265–76.
   PubMed Web of Science ®Google Scholar
• Lau UY, Benoit LT, Stevens NS, et al. (2018). Lactone stabilization is not a necessary feature for antibody conjugates of camptothecins. Mol Pharm 15:4063–72.
   PubMedGoogle Scholar
• Li J, Xiao D, Xie F, et al. (2021). Novel antibody-drug conjugate with UV-controlled cleavage mechanism for cytotoxin release. Bioorg Chem 111:104475.
   PubMed Web of Science ®Google Scholar
• Lyon RP, Bovee TD, Doronina SO, et al. (2015). Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol 33:733–5.
   PubMed Web of Science ®Google Scholar
• Nakada T, Sugihara K, Jikoh T, et al. (2019). The latest research and development into the antibody-drug conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull 67:173–85.
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Aida T, Hagihara K, et al. (2016). DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res 22:5097–108.
   PubMed Web of Science ®Google Scholar
• Schreiber AR, Andress M, Diamond JR. (2021). Tackling metastatic triple-negative breast cancer with sacituzumab govitecan. Expert Rev Anticancer Ther 21:1303–11.
   PubMed Web of Science ®Google Scholar
• Seligson JM, Patron AM, Berger MJ, et al. (2021). Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer. Ann Pharmacother 55:921–31.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM. (2012). Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther 11:224–34.
   PubMed Web of Science ®Google Scholar
• Shin WS, Han J, Kumar R, et al. (2016). Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor. Sci Rep 6:29018.
   PubMed Web of Science ®Google Scholar
• Sievers EL, Senter PD. (2013). Antibody-drug conjugates in cancer therapy. Annu Rev Med 64:15–29.
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Balar AV, Petrylak DP, et al. (2021). TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol 39:2474–85.
   PubMed Web of Science ®Google Scholar
• Tedeschini T, Campara B, Grigoletto A, et al. (2021). Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates. J Control Release 337:431–47.
   PubMed Web of Science ®Google Scholar
• Xiao D, Zhao L, Xie F, et al. (2021). A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate. Theranostics 11:2550–63.
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Takegawa N, Watanabe S, et al. (2019). An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC. Oncogene 38:1398–409.
   PubMed Web of Science ®Google Scholar